[HTML][HTML] A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer
Background ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI)
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer
RJ Kelly, FA Shepherd, A Krivoshik, F Jie… - Annals of …, 2019 - annalsofoncology.org
Background ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI)
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer
RJ Kelly, FA Shepherd, A Krivoshik, F Jie, L Horn - 2019 - ir.vanderbilt.edu
Background ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI)
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
[PDF][PDF] A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer
RJ Kelly, FA Shepherd, A Krivoshik… - Annals of …, 2019 - pdfs.semanticscholar.org
Background: ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI)
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
RJ Kelly, FA Shepherd, A Krivoshik, F Jie… - Annals of Oncology …, 2019 - europepmc.org
Background ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI)
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
[HTML][HTML] A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer
RJ Kelly, FA Shepherd, A Krivoshik, F Jie… - Annals of …, 2019 - ncbi.nlm.nih.gov
Background ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI)
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer
RJ Kelly, FA Shepherd, A Krivoshik… - Annals of oncology …, 2019 - pubmed.ncbi.nlm.nih.gov
Background ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI)
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …